Authors

Latest:

Investigators Seek Simpler Solution to Treatment Resistance in Esophageal Cancer

Although the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.

Bassam Sonbol, MD

Latest:

Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal Cancers

Mohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.

Manali Kamdar, MD

Manali Kamdar, MD, is an associate professor of Medicine-Hematology and the clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus in Aurora.

Latest:

Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Lakshmi Nayak, MD

Lakshmi Nayak, MD, is the director of the Center for Central Nervous System Lymphoma and a senior physician at Dana-Farber Cancer Institute. She is also an associate professor of neurology at Harvard Medical School.

Latest:

Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Lori Muffly, MD

Lori Muffly, MD, is an associate professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford Medicine.

Latest:

Dr Muffly on the Role of Obe-Cel in R/R B-Cell Precursor ALL

Dipenkumar Modi, MD

Latest:

Dr. Modi on the Utility of BTK Inhibitors in CLL

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Gabriel Hortobagyi, MD, MACP, FASCO

Latest:

Advances Treating HR+ Metastatic Breast Cancer

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Victor Moreno, MD, PhD

Latest:

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

Deepa Jagadeesh, MD

Latest:

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Peter Kozuch, MD

Latest:

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Tamas A. Gonda, MD

Latest:

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Looking to the Future

In this final episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, reiterate that the role of endoscopic therapies in pancreatic cancer continues to evolve.

Aristotelis Bamias, MD

Latest:

Dr. Bamias on Final Analysis of Atezolizumab Monotherapy in the IMvigor130 Trial in mUC

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Karisa C. Schreck, MD, PhD

Latest:

The FORTE Trial: Data for Plixorafenib in BRAF V600+ CNS Tumors

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss available data for plixorafenib in central nervous system tumors harboring BRAF V600 mutations from the FORTE trial.

Angeles Alvarez Secord, MD, MHSc

Latest:

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Jennifer Crombie, MD

Latest:

FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Jennifer Crombie, MD, shares insights about the FDA's approval of epcoritamab for patients with relapsed/refractory follicular lymphoma.

Samuel Kareff, MD, MPH

Latest:

The Importance of Hematology/Medical Oncology Fellowship

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

Barbara Melosky, MD, FRCPC

Latest:

Dr. Melosky on the Use of Lurbinectedin in SCLC

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Cassandra A. Hathaway, MD

Latest:

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Michael Chuong, MD, FACRO

Latest:

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.

Callie Coombs, MD

Latest:

Recognizing BTKi Resistance in CLL—Incorporating Pirtobrutinib in Relapsed/Refractory Disease

Panelists discuss how Bruton tyrosine kinase (BTK) resistance mutation testing is routinely performed at disease progression, but currently doesn’t change treatment decisions because pirtobrutinib shows comparable efficacy regardless of mutation status. However, high-level mutations (C481S or L528W) might favor venetoclax-based therapy over pirtobrutinib in second-line treatment. The panelists also emphasize the importance of patient education; approximately one-third of progressive patients lack detectable resistance mutations yet still require treatment changes based on clinical progression rather than molecular findings.